Correlation of Survival and Other Clinical Benefits With Imetelstat Therapy in High-Risk, JAK Inhibitor–Refractory Myelofibrosis

Clinical Care Options (CCO) commentary in which Dr. Daniel Pollyea provides his strategies for treating patients with myelodysplastic syndrome (MDS)

Daniel Pollyea, MD, MS Released: September 24, 2021

Gain key clinical insights quickly with this short slideset from Clinical Care Options (CCO) on CAR T-cell therapy

Caron A. Jacobson, MD Jae H. Park, MD Noopur Raje, MD Released: June 18, 2021

Enter characteristics of your patient with myelodysplastic syndrome (MDS) into this online tool to receive treatment recommendations from 5 experts.

Rami S. Komrokji, MD
Program Director Amy E. DeZern, MD, MHS Daniel Pollyea, MD, MS Michael J. Savona, MD Amer Zeidan, MBBS Released: May 14, 2021

Steven Waguespack, MD, on hypothyroidism after immune checkpoint inhibitors, MIBG treatment, or mitotane, and the mechanism of hyperthyroidism in cancer survivors from Clinical Care Options (CCO)

Steven G. Waguespack, MD Released: April 26, 2021